Epigenetic processes play a major role in normal mammalian development, particularly during gametogenesis and early embryogenesis. Thus, perturbation of epigenetic processes in the testis by xenobiotics could have a major impact on testicular function and fertility, and potentially affect the development and health of subsequent generations. There has been substantial research into the epigenetic toxicity of environmental exposures over the last decade. However, few studies have focussed on pharmaceutical drugs, which due to the nature of their use are typically found at much higher concentrations within exposed individuals than environmental chemicals. Here, we investigated genome-wide changes in testicular mRNA transcription, microRNA expression and DNA methylation to assess the contribution of epigenetic mechanisms to the testicular toxicity induced by doxorubicin (DOX) as a representative, widely used and well-characterised anti-cancer drug. We demonstrated that DOX is able to induce transcriptional, microRNA and DNA methylation changes, which perturb pathways involved in stress/cell death and survival and testicular function and lead to germ cell loss and reproductive organ damage. This identified potential novel mechanisms of DOX-induced testicular toxicity for further focussed investigations. Such work is required to fully assess the role of epigenetics in toxicity, determine whether single and/or multigenerational epigenetic toxicity is a real public health concern, and begin to develop and incorporate relevant epigenetic endpoints into regulatory toxicology. † Electronic supplementary information (ESI) available. See
Introduction
Cancer is an important Public Health issue, not only in terms of diagnosis and treatment but also the continued medical support of survivors. It is now estimated that over 2 million people in the UK are living with and beyond a diagnosis of cancer, 1 and that there are 14.5 million cancer survivors in the US. 2 Survivors of childhood cancers require careful follow-up as they have a greater risk of developing secondary cancers and chronic conditions in later life as a result of their previous treatments, and are more likely to want to go on to have their own children. The most common types of cancers in the UK and US in both childhood (0-15 years) and teenagers/young adults (15-24 years) are leukaemias and lymphomas, 1,2 the treatment of which normally involves DOX or another anthracycline. 3 With the overall 5 year survival rate of cancers diagnosed before the age of 25 now greater than 80%, there are currently 35 000 cancer survivors in the UK that were diagnosed before the age of 15, 1 and 388 501 cancer survivors in the US that were diagnosed before the age of 21. 2 It is estimated that around half of these will have been treated with an anthracycline. 3 The long term cardiotoxicity associated with anthracycline use is widely recognised in cancer survivors and has been extensively investigated mechanistically in various model systems (both by ourselves 4, 5 and others 6 ). However, much less is known about the long term effects of DOX, or other anthracyclines, on subsequent reproduction and development. There is some epidemiological evidence that chemotherapeutic treatment can be detrimental to later life reproductive function. [7] [8] [9] It is therefore important to investigate the testicular toxicity induced by chemotherapeutics like DOX. Such pharmaceuticals are widely prescribed to younger male cancer patients that may go on to father subsequent generations. To-date DOX has been associated with reduced testicular blood flow and volume, testicular atrophy, increased cellular apoptosis, altered spermatogenesis, increased sperm abnormalities and reduced sperm counts and fertility. [10] [11] [12] [13] [14] [15] [16] [17] Nevertheless, the molecular mechanisms underlying DOX-induced testicular toxicity, particularly epigenetic processes, remain underexplored.
Epigenetics encompasses the mechanisms that regulate gene expression without altering the underlying DNA sequence, including DNA methylation, histone modification and non-coding RNAs (ncRNAs) (such as microRNAs (miRNAs), piwi-interacting RNAs ( piRNAs) and endogenous siRNAs (esiRNAs)). These epigenetic processes play vital roles during mammalian development. 18 Briefly, the mammalian life cycle involves two genome-wide epigenetic re-programming and programming events. The first event occurs immediately after fertilisation to reset the embryonic genome so that it is capable of producing all of the different cell types necessary to form a new individual, and subsequently drive the cellular proliferation and differentiation processes involved in development of the offspring through embryogenesis and into a mature adult. The second event involves the primordial germ cells (PGCs) only. It functions to reset all of the future germ cells according to the gender of the embryo, ( parentally imprinted genes must be correctly reset to enable the production of future generations), and subsequently drive gametogenesis. Both of these events involve genome-wide DNA demethylation and changes in histone modifications and noncoding RNA expression to effectively 'wipe clean' the embryonic and germ cell epigenomes, followed by genome-wide DNA remethylation, and further changes in histone modifications and non-coding RNA expression to redirect and regulate the proceeding development.
These epigenetic mechanisms do not function independently; they interact to regulate gene expression at multiple levels. This helps to confer efficiency, redundancy, robustness and fidelity onto epigenetic re-programming/programming during development, and thus the successful and continued production of multiple generations. 18 While such complex networks exist to maintain cellular homeostasis, they are open to perturbation. A wide range of environmental factors have been shown to induce epigenetically-mediated adverse phenotypes in rodent models and can be linked with epigenetic changes and adverse outcomes in human epidemiological cohorts, leading to the "Developmental Origins of Health and Disease" (DOHaD) hypothesis. 18 Indeed, a number of recent independent studies have demonstrated that early life trauma or parental stress can induce altered miRNA expression in sperm, which in turn can transmit behavioural and metabolic abnormalities through to the next generation. [19] [20] [21] There is also evidence that DNA methylation changes and histone modifications in the male germline could transmit unique epigenetic information to activate and regulate early embryo development in the next generation. [22] [23] [24] [25] Any change that becomes permanently established in the germline could continue to adversely affect subsequent generations, even in the absence of the original exposure, leading to so-called transgenerational toxicity. There is concern that pharmaceuticals could also induce similar epigenetic toxicity. 26 Furthermore, it has been demonstrated in rodent models that paternal anticancer drug exposure can increase genomic instability in the treated animals and their resulting offspring, 27 and paternal DOX exposures can induce adverse developmental phenotypes in subsequent zygotes. 13, [28] [29] [30] In order to improve our understanding of the epigenetic mechanism(s) involved in pharmaceutical-induced testicular toxicity, we selected DOX as a representative, widely-used and well-characterised anti-cancer drug. We used a dosing method (3 doses of 3 mg −1 kg wk −1 ) previously shown to induce testicular toxicity in rodents. 11, 13, 31 A total dose of 9 mg kg −1 equates to 27 mg m −2 in a typical 60 kg human (using the recommended body surface area normalisation method for conversion). 32 This is 17-20× lower than the maximum cumulative dose of 450-550 mg m −2 used in cancer treatment protocols. Since epigenetic processes interact to regulate gene expression at multiple system levels, we analysed genome-wide changes in mRNA and miRNA expression, and DNA methylation, alongside toxicological endpoints in mice treated with DOX. These data provided a greater understanding of the epigenetic and transcriptional processes that contribute to DOX-induced testicular toxicity, and related specific epigenetic and transcriptional changes to actual phenotypic endpoints. Such changes are useful for informing further focused studies on DOXinduced epigenetic testicular toxicity.
Materials & methods

Materials
All materials, including DOX (as doxorubicin hydrochloride) were purchased from Sigma Aldrich, UK unless otherwise stated.
In vivo model
Animal experimentation, transportation and care were performed in compliance with the Animal Scientific Procedures Act (1986) under project licenses 80/2126 and 30/3021, and approved by local ethical review committees at the University of Leicester or the Centre for Radiation, Chemical and Environmental Hazards, Public Health England. C57BL/6J male mice (8 week of age and weighing 18-25 g) were housed and fed ad libitum food and water with a 12 h light/dark cycle, and acclimatised for 1 week prior to dosing. DOX was dissolved in 0.85% (v/v) saline to a working dilution of 0.3 mg ml −1 and administered via intraperitoneal injection (ip). Animals received either 3 mg kg −1 DOX (n = 6) or vehicle-only (0.85% (v/v) saline) (n = 6) once per week for 3 week, resulting in a total dose of 9 mg kg −1 . Animals were then sacrificed at 1, 4 or 7 week following the final drug administration as described below. Twelve animals were used for each of the time points, 6 control and 6 treated in each group.
Animals were anaesthetised with isofluorane, blood was collected by cardiac puncture and organs were perfused with 10 ml of PBS (Life Technlogies, UK). Animals were then sacrificed by cervical dislocation and organs (testes, caudal epididymis and seminal vesicles) were removed, weighed, immediately snap frozen in liquid nitrogen and stored at −80°C until further analysis. Separate animal experiments were conducted to generate testis samples for histopathological analysis. Paired testes were pierced at each end with a needle and one testis was placed in Bouin's fixative, whilst the second testis (from the same animal) was placed in Zenker's fixative for 24 h prior to histological processing.
Histopathological analysis
Paired Bouin's and Zenker's fixed testes were washed directly under running water for 24 h, followed by dehydration in 70% alcohol for a further 24 h. Dehydrated testes were then embedded in paraffin wax and stored at 4°C until sectioning. Paraffin-embedded testes were cut into 5 μm sections on a RM2155 microtome (Leica Microsystems, Switzerland), mounted onto glass slides, stained with H&E or PAS and viewed and imaged using Leica Application Suite Version 3.8 software on a DM2000 microscope connected to a DFC450C camera (Leica Microsystems, Switzerland). Following identification and confirmation of each type of germ cell population in the seminiferous tubule (spermatogonia, spermatocytes, round spermatids and elongated spermatids), the presence of each germ cell population per seminiferous tubule within the field of view (40× magnification) was calculated as a percentage.
Sperm count
Caudal epididymides from individual animals were finely chopped in a petri dish (Sarstedt, Germany), collected in 1 ml PBS and passed through a CD-1TM 190 μm mesh screen. A C-Chip disposable haemocytometer (PAA, UK) was used to count 10 μl of the resulting sperm suspension. The total number of sperm per caudal epididymides was calculated as number of sperm heads per ml.
Nucleic acid profiling
RNA or DNA were extracted from frozen testis using either Tri reagent or a DNeasy Blood and Tissue kit (Qiagen, Germany), respectively, according to the manufacturer's instructions. RNA was stored at −80°C and DNA at −20°C until microarray analysis. RNA integrity was determined using a 2100 Bioanalyser and RNA 6000 LabChip® kit (Agilent Technologies, USA) according to the manufacturer's instructions. Only RNA samples with an RNA integrity number (RIN) ≥ 8.0 were used for downstream analysis.
mRNA (transcriptional) microarrays
Genome-wide changes in testicular mRNA expression were profiled using microarrays obtained from the Medical Research Council Toxicology Unit (Leicester, UK). These microarrays were printed in-house using an inkjet style ArrayJet Ultra-Marathon II microarray printer (ArrayJet, Roslin, Scotland) and the Mouse Exonic Evidence-Based Oligonucleotide (MEEBO) probe set (Life Technologies, UK). The MEEBO microarrays included a total of 39 000 probes that provided complete coverage of the mouse genome. RNA (200 ng) was amplified and labelled with a Two-Colour Low Input Quick Amp Labelling Kit (Agilent Technologies, USA) according to the manufacturer's instructions and included a dye-swap to avoid dye bias (n ≥ 3 for both forward and reverse labelling). cDNA concentration and efficiency of cDNA labelling was measured with a NanoDrop ND-1000 spectrophotometer. Only cDNA samples with a concentration ≥200 ng μl −1 and Cy3/Cy5 labelling ≥5 pmol μl −1 were used for hybridisation. Control and treated samples were randomly paired and pooled so that the concentrations of Cy3 and Cy5 cDNA were equal and dried down to a final volume of 9 μl prior to the addition of 1 μl fragmentation reagent (Ambion, UK). Samples were incubated for 15 min at 70°C. The fragmentation reaction was terminated by the addition of 1 μl stop solution (Ambion, UK) and incubation for 5 min on ice, followed by addition of 28 μl ultra-pure water (Thermofisher, UK), 1 μl yeast tRNA (4 mg ml −1 ) and 40 μl 2× enhanced hybridisation buffer (Genisphere, USA). Samples were then denatured for 5 min at 100°C and incubated for 30 min at 42°C prior to hybridisation on the MEEBO microarrays overnight at 42°C. Microarray slides were washed on a rocking platform (Scientific Laboratory Supplies, UK) set at 50 oscillations per min for 5 min each at RT, firstly in 1× SSC containing 0.03% (w/v) SDS, secondly in 0.2× SSC and finally in 0.05× SSC. Slides were dried by centrifugation at 1200g for 4 min at RT and scanned on a 4200A Axon scanner (Molecular Devices, CA) at wavelengths of 532 and 635 nm and a resolution of 5 μm using GenePix 6.0 software (Molecular Devices, CA).
miRNA microarrays
Genome-wide changes in testicular miRNA expression were profiled using microarrays also obtained from the Medical Research Council Toxicology Unit (Leicester, UK), printed inhouse using the printer described above and the miRCURY LNA™ probe set (Exiqon, Denmark). The miRCURY probe set included a total of 1500 probes that provided complete coverage of version 8.0 of miRBase. RNA (500 ng) was labelled with either the Flashtag™ RNA Labelling Kit (Genisphere, USA) or the Label IT® miRNA labelling kit (Mirus, USA) according to the manufacturer's instructions (except that all reactions were halved) and included a dye-swap to avoid dye bias (n ≥ 6 for both forward and reverse labelling). Control and treated samples were randomly paired and pooled so that the concentrations of Cy3 and Cy5 cDNA were equal and treated according to the labelling kit's manufacturer's instructions. Samples were then denatured for 3-10 min at 65°C and incubated for 30 min at 37°C prior to hybridisation on the miRCURY microarrays overnight at 37°C. Microarray slides were washed firstly in 2× SCC containing 0.05% (w/v) SDS, secondly in 1× SSC and finally in 0.5× SSC, dried by centrifugation, and scanned as described above.
DNA methylation arrays
Genome-wide changes in testicular DNA methylation were profiled using MM9 CpG Refseq Prom MeDIP microarrays purchased from Roche NimbleGen (Roche, USA). These microarrays included a total of 720 000 probes designed to cover all CpG islands within gene bodies and the known promoter regions of genes in the mouse genome version mm9. Immunoprecipitation of methylated DNA was carried out according to Nimble-Gen DNA Methylation Services: sample preparation instructions v4.1 (Roche, USA). Labelling and hybridisation of input and immunoprecipitated samples, followed by washing and scanning of microarrays was carried out according to NimbleGen Arrays User's Guide: Epigenetics Arrays v1.0 using a NimbleGen Hybridisation System 4, a MS 200 Microarray scanner and the MS Data Collection Software (Roche, USA).
Bioinformatic analysis
mRNA and miRNA expression. Pixel intensities were annotated to mouse reference files (mRNAs and miRNAs) and extracted using GenePix pro 6.0 (Molecular Devices, CA). These raw data files were normalised using the LOESS within array followed by the quantile between array commands in the Bioconductor limma library package of R version 2.15.2 (http:// www.r-project.org/). Normalised log 2 [Cy5/Cy3] ratios were compiled into a spreadsheet and imported into Qlucore Omics Explorer (QOE) version 2.3 (Qlucore, Sweden) to identify statistically significant differentially expressed transcripts or miRNAs ( p < 0.001, q < 0.01 significance level, where q represents a multiple comparison correction with a false discovery rate of 1%) at each time point following DOX treatment. Lists containing the top 100 most significantly differentially expressed transcripts or miRNAs over time were imported into Ingenuity® Pathway Analysis Software ((IPA®), Ingenuity® Systems http://www.ingenuity.com/products/ipa) to explore the mRNA and miRNA networks and pathways involved in DOXinduced testicular toxicity.
DNA methylation changes. Data was analysed using DEVA Software User Guide version 1.2 (RocheNimbleGen, USA) according to the manufacturer's instructions. Briefly, log 2 -[Immunoprecipitated/Input] ratios were calculated and assigned a probability score (p value) by performing a Kolmogorov-Smirnov test on several adjacent probes using a sliding window set at 750 bp with overlapping 500 bp spacing. From this p value, the peak score was calculated by combining four consecutive probes per peak and values ≥2 were identified as methylated peaks. These peaks were mapped to annotation files provided by Roche NimbleGen to generate a spreadsheet of peak values mapped to their associated gene. To obtain a value for the difference between control and treated samples, the ratio of the peak score ( peak score DOX-peak score control) was calculated. These ratios were compiled into a spreadsheet and imported into QOE to identify statistically significant differentially methylated genes ( p < 0.001, q < 0.01 significance level, where q represents a multiple comparison correction with a false discovery rate of 1%) at each time point following DOX treatment. A list containing the top 100 most significantly differentially methylated regions (DMRs) over time were imported into IPA® to explore the differentially methylated gene networks and pathways involved in DOX-induced testicular toxicity, and correlated with the list of the top 100 most significantly differentially expressed mRNA transcripts.
Raw data files for all three datasets have been submitted to GEO: mRNA (GEO***), miRNA (GEO***) and DNA methylation (GEO***).
Real-time PCR validation. Microarray results were validated by qRT-PCR using either a 7500 Fast (Life Technologies, UK) or a Rotor-Gene Q (Qiagen, Germany) qRT-PCR System.
mRNA qRT-PCR. Synthesis of cDNA was performed using either a High Capacity RNA to cDNA Kit (Life Technologies, UK) or a QuantiTecT Reverse Transcription Kit (Qiagen, Germany) according to the manufacturer's instructions. The resulting cDNA was diluted with ultrapure water/1× TE (10 mM Tris-HCl ( pH 8.0), 0.1 mM EDTA) to a final concentration equivalent to 10-100 ng RNA input. 1 µl diluted cDNA was analysed by qPCR in a 20-25 µl reaction containing 200 nM primers and 10-12.5 µl of either 2× Power Sybr Green Master Mix (Life Technologies, UK) or 2× Perfecta Sybr Green Supermix (Quanta Biosciences, USA) according to the manufacturer's instructions. Relative mRNA expression was calculated using the delta Ct method and Gapdh as an endogenous control. All primer sequences are shown in ESI Table 1 . † miRNA qRT-PCR. Synthesis of cDNA was performed using a qScript microRNA cDNA Synthesis Kit (Quanta BioSciences, USA) according to the manufacturer's instructions. The resulting cDNA was diluted with 1× TE to a final concentration equivalent to 10 ng RNA input. 4 μl of diluted cDNA was analysed by qPCR in a 20 µl reaction containing 250 nM microRNA primer (Integrated DNA Technologies, UK), 250 nM perfecta universal pcr primer (Integrated DNA Technologies, UK) and 10 μl 2× perfecta SYBR green supermix (Quanta BioSciences, USA) according to the manufacturer's instructions. Relative miRNA expression was calculated using the delta Ct method and RNU6 as an endogenous control.
Results
DOX induced testicular toxicity
Reductions in the weight of testes, caudal epididymides and seminal vesicles, and the concentration of sperm within the caudal epididymides were observed following DOX treatment ( Fig. 1) . A number of these decreases were time-dependent and 
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Toxicology Research were reflected in the histopathological analysis of the testes. Testicular sections were examined using two different fixatives (Bouin's and Zenker's), each with two different staining techniques (H&E and PAS) to ensure that all relevant cell types could be clearly identified and counted (for further information see ESI Fig. 1 †) . A representative image showing the identification of different testicular cell populations is presented in Fig. 2A . Control testis exhibited normal morphology of the seminiferous and interstitial tubules at all time points ( Fig. 2C , E & G). Seminiferous tubules consisted of Sertoli cells and well organised germ cells, with progressive differentiation from spermatogonia in the basal compartment moving inwards through spermatocytes and round spermatids to elongated spermatids close to release into the lumen. Elongated spermatids demonstrated intact maturation with formation of the acrosomal cap and Leydig cells were present within the interstitial tubules. In contrast, testis treated with DOX displayed disorganised seminiferous tubules with shrinkage, vacuolisation and some level of germ cell depletion at all time points ( Fig. 2D, F & H) . At 1 week post-treatment germ cells at earlier stages of spermatogenesis (spermatogonia, spermatocytes and even round spermatids) were absent; whilst more mature elongated spermatids close to an abnormal, but discernible, lumen were present (Fig. 2D ). As in control animals, these elongated spermatids showed intact maturation with formation of the acrosomal cap. However, unlike those in the control animals, the DOX exposed elongated spermatids appeared to be arrested in the germinal epithelium, with no evidence of release by any of the seminiferous tubules. Spermatogenesis is a continual process. Thus, at any point in time, different seminiferous tubules will be at different stages of sperm production. This is reflected in the control animals with the release, and therefore absence, of elongated spermatids from a proportion of the seminiferous tubules (Fig. 2C) . In contrast, all of the seminiferous tubules in the treated animals contain elongated spermatids, which, together with the lack of spermatogonia, spermatocytes and round spermatids, suggests arrest of spermatogenesis at 1 week post-treatment ( Fig. 2D ). By 4 week post-treatment seminiferous tubules were distinctly atrophied and showed a Sertoli-only syndrome with a lack of lumen and all germ cells (Fig. 2F ). However, at 7 week posttreatment, although the majority of seminiferous tubules remained atrophied and showed a Sertoli-only syndrome, some had begun to show signs of recovery with the presence of spermatogonia and spermatocytes (Fig. 2H ). This increased sensitivity of germ cells at earlier stages of spermatogenesis to DOX-induced toxicity compared to the more mature elongated spermatids with an intact acrosomal cap, followed by some subsequent recovery, is particularly well highlighted by presenting the number of spermatogonia, spermatocytes, round spermatids or elongated spermatids per seminiferous tubule over time (Fig. 2B) . The apparent increased number of elongated spermatids in the seminiferous tubules of the animals at 1 week post-treatment reflects the arrest of spermatogenesis. It is also worth noting that while Leydig cells were present in both control and DOX treated testes, there appeared to be signs of Leydig cell hyperplasia following DOX exposure, particularly at 4 and 7 week post-treatment.
In summary, treatment with DOX induced significant testicular atrophy, (involving progressive loss of germ cells leading to reduced sperm counts and Leydig cell hyperplasia), with evidence of some recovery at 7 week.
DOX perturbed both transcriptomic and epigenetic testicular profiles DOX induced the differential expression of approximately 700 transcripts and 200 miRNAs at the p < 0.001, q < 0.01 significance level (q represents a multiple comparison correction with a false discovery rate of 1%), with the 4 week post-treatment group demonstrating the greatest level of change. The top 100 most statistically significant changes over time, corresponding to 96 mRNAs and 75 miRNAs, are shown in Fig. 3 & 4 .
Those mRNAs and miRNAs of particular interest, due to either differential expression at more than one time point and from literature searches identifying their role in male infertility and tissue atrophy, were validated by qRT-PCR (Table 1) . Validated mRNA transcripts were classified into groups based on their biological and physiological roles; testicular function, stress/cell death and survival, or DNA methylation. Of the 9 transcripts with roles in testicular functions, 7 (Catsper1 & 3, Crem, Hspa2, Nme5, Stra8 and Tnp2) were downregulated and 2 (Cyp17a1 and Insl3) were upregulated following treatment with DOX. In contrast, of the 10 stress/cell death and survival transcripts, 9 (Bcl2, Casp3, Casp6, Ctsb, Ctsd, Ctss, Ctsw, Gstm3 and Tcf21) were upregulated and 1 (Hspa1a) was downregulated post DOX exposure. DOX also induced downregulation of the DNA methyltransferase (Dnmt ) family transcripts, with Dnmt3l demonstrating the greatest level of change. A total of 5 miRNAs (miRs-26a, 29a-c and 145) were subsequently validated due to their common targeting of the DNA methyltransferase family (mRNA targets of the 5 miRNAs were identified using miRwalk 33 ) and their pro-apoptotic functions. [34] [35] [36] [37] [38] All 5 of these miRNAs were upregulated at two or more time points following DOX exposure, with the greatest level of change at 4 week post-treatment. All of the qRT-PCR results were in agreement with the microarray data (ESI Table 2 †).
The inverse correlation in expression of the Dnmt family transcripts with that of miRNAs known to target them suggested that DOX may disrupt methylation patterns within the testis. Therefore, genome-wide changes in testicular DNA methylation were also analysed. DOX induced the differential methylation of over 450 regions at the p < 0.001, q < 0.01 significance level (q represents a multiple comparison correction with a false discovery rate of 1%). The top 126 most significantly DMRs over time are shown in Fig. 5A . Of these 126 DMRs, 99 were associated with known genes, mapping to regions within the promoter or gene body (Fig. 5B ). Distribution of the top 126 DMRs appeared to be largely random, being located on the majority of chromosomes with the highest proportion on chromosome 2 and the X chromosome ( Fig. 5C ). 
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Finally, significantly DMRs associated with known genes and significantly differentially expressed mRNA transcripts (p ≤ 0.001) were compared. This identified 6 inverse correlations, 3 of which (Hook1, Spag16 and Stam) were identified in the literature as being involved in testicular and reproductive function. All 3 displayed a general increase in DNA methylation and decrease in mRNA expression over time (ESI Table 3 
†).
In summary, treatment with DOX induced significant changes in mRNA and miRNA expression and DNA methylation that were associated with biological pathways relevant to the observed testicular toxicity.
DOX induced transcriptomic and epigenetic changes in pathways associated with developmental and reproductive system disease
The most statistically significant transcriptional and epigenetic changes, corresponding to 96 mRNAs, 75 miRNAs and 99 gene-associated DMRs ( p ≤ 0.001) were selected for more focussed functional analyses using IPA software. This revealed roles for altered transcripts and miRNAs in various molecular and cellular functions including three major networks concerning cancer and cellular, tissue, organ and embryonic development, developmental disorders and reproductive system disease. Of the 36 canonical pathways identified, the top two were involved in oxidative stress related pathways such as glutathione-mediated detoxification and NRF-2 mediated oxidative stress response. Furthermore, 15 of the altered transcripts were also particularly relevant for the proper development and function of the reproductive system and the successful progression of spermatogenesis ( Table 2) ; 9 of the 12 altered miRNAs important in reproductive system abnormalities (let-7 family, and miRs-141-5p, 145, 190b, 767, 539-5p, 339-5p, 29b and 9-3p) have also been shown to be altered in men with non-obstructive azoospermia; and 4 of the DMRs (Cdkn2a, Foxm1, Vezt and Zfx) were associated with genes involved in reproductive system development and disease.
In summary, treatment with DOX induced transcriptomic and epigenetic changes in pathways associated with developmental disorders and reproductive system disease.
Discussion
Spermatogenesis is a complex developmental process that involves proliferation and differentiation of diploid spermatogonia to haploid spermatozoa, with the support of endocrine secretion and other cellular signals from Leydig and Sertoli cells (reviewed in ref. [39] [40] [41] [42] . Compound-induced damage to any of the testicular cell types could affect the production of healthy spermatozoa and therefore impede fertility and potentially adversely affect the resulting embryo. Previous studies in rodents have demonstrated that treatment with DOX causes damage to the male reproductive system with further implications in fertility and developmental processes. For example, DOX has been shown to induce decreased sperm counts with altered sperm morphology, germ cell death, vacuolated semini- 
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Toxicology Research ferous tubules, infertility and damage to the developing embryo. 28, 29, [43] [44] [45] To date, limited data is available on studies comparing genome-wide toxicogenomic data (transcriptional, miRNA or DNA methylation changes) with pathological alterations in the testis following DOX exposure. The present study was therefore conducted to link molecular transcriptomic and epigenetic changes in the testes following DOX treatment with phenotypic outcome, thereby exploring novel mechanisms of DOX-induced testicular toxicity and highlighting those for further focussed study.
In keeping with the current literature, treatment with DOX induced organ atrophy, reduced sperm counts and long term damage to the seminiferous tubules within the testes (Fig. 1-2 ). Even 7 week post-treatment, when enough time had elapsed since DOX exposure for a complete cycle of spermatogenesis (35 days in the mouse), only 3-8% of seminiferous tubules showed repopulation with differentiating spermatogonia and spermatocytes. This does suggest, however, that some spermatogonial stem cells survive and eventually regain their differentiating capacity. Similar long term murine DOXinduced testicular toxicity has previously been reported, where the rate of fertility was decreased up to 32 weeks post-treatment, and sperm counts or morphology did not return to normal until 1 year post DOX-treatment. 28 Atrophy of the testes and caudal epididymides correlated with, and thus appeared to be largely due to, testicular germ cell loss and decreased sperm production. Furthermore, germ cells at the earlier stages of spermatogenesis (spermatogonia, spermatocytes and round spermatids) appeared to be more sensitive to DOX exposure than those in the latter stages (elongated spermatids). In contrast, Leydig and Sertoli cells showed greater resistance to DOX exposure. While there was no evidence of Sertoli cell toxicity, there did appear to be some Leydig cell hyperplasia, particularly at 4 and 7 week post-treatment. Such hyperplasia has also been reported in rats following treatment with other testicular toxicants such as di-(2ethylhexyl) phthalate, 46 and may represent a compensatory response to the loss of germ cells.
Differing sensitivities to DOX, and thus the ultimate toxicities observed following DOX treatment, are likely to be the combined result of three main factors; (1) the presence of physiological barriers such as the blood-testes barrier (BTB), the blood-epididymis barrier (BEB) and the acrosomal cap, (2) the specific expression of efflux pump transporters on the surface of different germ/testicular cell types, and (3) the proliferative/differentiation status of different germ/testicular cell types. The BTB separates the seminiferous tubule into basal and adluminal compartments and prevents the accumulation of xenobiotics in the latter. Spermatogenesis begins with division of the testicular stem cells (spermatogonia) within the basal layer. As the spermatogonia divide and differentiate into spermatocytes and spermatids they move through the BTB into the protected adluminal compartment. Thus, those spermatocytes and spermatids within the adluminal compartment of the testes, and the spermatozoa within the BEB of the caudal epididymides, are provided greater protection from circulating DOX. Formation of the acrosomal cap during spermatid differentiation provides another physiological barrier that may protect the elongated spermatids and spermatozoa from DOXinduced toxicity. In addition, different germ/testicular cells have subtle variations in the type and level of expression of transporters such as efflux pumps. [47] [48] [49] The type and number of such pumps within each of the different cell types will therefore also contribute to the final intracellular levels of DOX. Finally, the proliferative/differentiation status of each germ/testicular cell type varies. Unlike spermatids, spermatogonia and spermatocytes undergo active proliferation and DNA synthesis in addition to differentiation. A predominant mechanism of action/toxicity of DOX is DNA intercalation and inhibition of DNA synthesis (hence its use as an anti-cancer agent). DOX can therefore impair the mitotic activity of, and DNA synthesis within, spermatogonia and spermatocytes, thus preventing the downstream progression of spermatogenesis and inducing cell death. In contrast, Leydig and Sertoli cells are terminally differentiated and do not normally undergo mitotic division in the sexually mature testis, thereby limiting DOX intercalation with DNA and reducing any cytotoxic effects. The subsequent genome-wide analysis of transcriptional and epigenetic changes induced by treatment with DOX combined with integrative bioinformatic analyses proved effective for providing further insights into molecular mechanisms of the DOX-induced testicular toxicity described above. In particular, DOX exposure altered the expression of mRNAs and miRNAs involved in testicular function, stress/cell death and survival, and DNA methylation (Table 1) .
Transcripts expressed in germ cells during different stages of spermatogenesis (Catsper1, Catsper3, Crem, Hspa2, Nme5, Stra8 and Tnp2) were all downregulated following DOX exposure. Such changes, particularly those that occur within the earlier stages of spermatogenesis (in spermatogonia, spermatocytes and round spermatids), are likely to be associated with the loss of germ cells and long term infertility resulting from DOX-induced testicular toxicity. In contrast, the 2 transcripts associated with hormonal functions within the testis (Cyp17a1 and Insl3) were upregulated. Likewise, 2 additional transcripts with roles in steroid biosynthesis (Fads1 and Fads2), also identified in the top 100 differentially expressed transcripts post DOX exposure but not further validated, were upregulated. Protocols using higher doses of DOX to induce testicular toxicity, where measurements were taken within a few hours or days following treatment, have been shown to reduce serum testosterone levels. [50] [51] [52] [53] However, other studies employing similar treatment procedures to the one used here, with lower doses of DOX and a delay between DOX exposure and effect measurement, have reported no change in serum testosterone levels during DOX-induced testicular toxicity (hence no serum measurements were performed here). 10, 54, 55 The increased expression of transcripts involved in steroid and androgen biosynthesis could thus be a compensatory mechanism to maintain testicular hormone homeostasis and/or stimulate production of more germ cells to replace those that have been lost or damaged as a result of DOX-induced toxicity, and/ or a simple reflection of an increase in the number of Leydig cells due to the observed Leydig cell hyperplasia. Changes in the expression of Cyp17a1 and/or Insl3 have been reported in numerous studies investigating Leydig cell toxicity and the effects of chemicals on testicular function. 46, [56] [57] [58] [59] [60] DOX also induced upregulation of mRNAs and miRNAs involved in apoptotic cell death pathways, including caspases (Casp3 and Casp6), cathespins (Ctsb, Ctsd, Ctss and Ctsw), and miRs 145, 26a and 29a-b. The greater upregulation of cathespins compared to caspases provides evidence for a redox stress related mechanism of DOX-induced testicular cytotoxicity. This is in keeping with the altered expression of mRNAs involved in cellular responses to oxidative stress reported here (Gstm3 and Nme5) and previous studies on the mechanisms of DOX-induced toxicity in both the testis and other organs. [61] [62] [63] [64] [65] In addition, miRs-145, 26a and 29a-c have also been shown to act as pro-apoptotic regulators. [34] [35] [36] [37] [38] It is therefore possible that induction of miR-145, miR-26a and the miR-29 family regulate DOX-induced germ cell death. This is unlikely to involve Bcl-2 repression as Bcl-2 mRNA was shown to be upregulated in the DOX samples. However, other proapoptotic mechanisms may be involved.
The same miRNAs (miRs-145, 26a, and 29a-c) are also known to target the Dnmt family (miRwalk 33 ). Upregulation of these miRNAs inversely correlated with the downregulation of the Dnmt family transcripts following DOX exposure. This is in agreement with a similar study in rats where members of the miR-29 family were upregulated and Dnmt transcripts were downregulated following exposure to xenoestrogens. 38 Such miRNA-mediated reduction of Dnmt transcripts could potentially lead to abnormal DNA methylation within the testis, thus DOX-induced genome-wide changes in testicular DNA methylation were also analysed. A significant change in the methylome of the testis was observed over time following treatment with DOX (Fig. 5 ). The highest proportions of these DOX-induced DMRs were located on chromosome 2 and the X chromosome, whilst no DMRs were observed on the X chromosome in control animals over time (ESI Fig. 2 †) . This may indicate a particular susceptibility of the X chromosome to aberrant methylation occurring from DOX-induced toxicity. A large number of genes expressed in germ/testicular cells are located on the X chromosome and the DMRs associated with these genes tend to be hypomethylated. 66 In general, DOX induced increased methyl- The top 96 most significantly differentially expressed mRNAs (p ≤ 0.001) were subjected to pathway analysis using IPA software, identifying 15 transcripts involved in the proper development and function of the reproductive system and the successful progression of spermatogenesis. 
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ation of X-linked DMRs over time, which could lead to the repression of genes involved in testicular function and ultimately contribute to the observed germ cell loss. One of the main mechanisms by which DOX has been shown to exert cytotoxicity is via p53-mediated apoptosis, 67, 68 and a number of apoptosis related transcripts and miRNAs have been identified here. In keeping with this, p53 signalling was the most significantly differentially methylated canonical pathway following DOX treatment. Furthermore, two genes within this pathway that also play significant roles in spermatogenesis (Cdkn2a and Pcna) demonstrated increased methylation post DOX exposure. Increased methylation and thus repression of genes involved in early spermatogenesis could be one of the key factors driving the germ cell loss following DOX treatment.
Comparison of the DNA methylation and transcriptional profiles revealed some correlation between methylation status and transcript expression following treatment with DOX. All showed increased methylation with a corresponding decreased level of expression over time post DOX exposure (ESI Table 3 †). Amongst those identified, Hook1, Spag16 and Stam are known to play significant roles in testicular and reproductive function. Such changes, particularly Hook1 and Spag16, may also contribute to DOX-induced germ cell loss. It is worth noting, however, that less than 2% of the gene-associated DMRs correlated with the differentially altered transcripts. This could reflect the complexities of correlating large genome-wide data sets performed on different platforms, or suggest that DNA methylation is not a predominant regulator of gene expression during DOX-induced testicular toxicity. Indeed, a recent study in vitro has shown that genome-wide changes in DNA methylation can have limited transcriptional consequences. 69 Thus, DNA methylation (or miRNA expression) changes may not always be mechanistically involved in toxicity, instead they may simply act as markers of exposure/toxicity. Both causal and consequential epigenetic markers could be of potential benefit in the clinic. For example, the 9 miRNAs altered by DOX that have also been shown to be differentially expressed in men with non-obstructive azoospermia may represent useful novel clinical markers of testicular/reproductive toxicity.
A number of the testicular transcriptional and epigenetic changes following DOX treatment were also associated with developmental and reproductive system disease. This is in keeping with the observed adverse developmental phenotypes in the offspring of male mice treated with DOX. [28] [29] [30] and the wider literature demonstrating that epigenetic changes induced by environmental factors and pharmaceutical drugs can cause harmful outcomes in future progeny via the male germline. [18] [19] [20] 27 This could be of particular concern for male cancer survivors that want to go on to have children. Treatment may not only affect their own reproductive function, but could potentially also have detrimental effects on the development of their future offspring.
The systems biology approach employed in this study has enabled the successful correlation of multiple datasets to explore the associations between epigenetic processes and toxic end points ( Fig. 6 ). Such genome-wide analysis is challenging and highlights the complexity involved in the regulation of gene expression. Nevertheless, potential epigenetic mechanisms and/or markers of DOX-induced testicular toxicity were identified from the correlation of large datasets. Further insight into which of these are the key players in DOX-induced testicular toxicity could begin with Western blot validation of mRNA changes of interest and/or validation of the DNA methylation status of genes demonstrating a negative correlation between methylation status and mRNA expression, before moving onto focussed mechanistic studies in appropriate in vitro models. Such applied work is required to determine relevance to humans and fully assess whether single and/or multigenerational epigenetic toxicity is a real public health concern.
Conclusions Perturbation of epigenetic processes is a concern, particularly in relation to reproductive toxicity and early development, Fig. 6 Correlation of multiple genome-wide datasets. Gene expression is regulated by multiple mechanisms at multiple levels, including DNA methylation (transcriptional level) and miRNAs ( post-transcriptional level). DNA methylation generally represses the transcription of genes and miRNAs; whilst miRNAs induce mRNA degradation or inhibit mRNA translation. Analysis of genome-wide changes in miRNA expression (the miRome), DNA methylation (the methylome) and mRNA levels (the transcriptome) identified potential epigenetic mechanisms and/or markers of DOX-induced testicular toxicity. DOX induced changes in the miRome, methylome and transcriptome that appeared to be related to the observed testicular toxicity (germ cell loss) and warrant further investigation.
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Toxicology Research since these are particularly vulnerable epigenetic windows and changes could affect future generations. Here we have shown that DOX is able to induce transcriptional, miRNA and DNA methylation changes, which perturb pathways involved in stress/cell death and survival and testicular function and lead to germ cell loss and reproductive organ damage. There are many levels of control involved in gene expression. Considering them together in a more systems based approach is critical for understanding the complex mechanisms involved in compound-induced toxicity, and for informing further focused studies. Like many others we therefore propose that toxicity testing should include an epigenetic element. Further elucidation of relevant epigenetic mechanisms are required in order for such tests to be developed and incorporated into regulatory toxicology.
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